Dr. Yan Ni is an Executive Director of Biomarkers and Precision Medicine at Passage Bio. The Biomarkers and Precision Medicine team is responsible for the overall biomarker strategic planning and execution for all clinical and preclinical programs in the Passage Bio research portfolio. Before Passage Bio, Yan was an Associate Director at the Precision Medicine Group of Regeneron Pharmaceuticals and was responsible for clinical biomarker planning and implementation for multiple disease areas from First-in-human to phase III. Yan also worked in the BioAnalytical Sciences Department at Bristol-Myers Squibb for five years, where she honed her expertise in clinical biomarker assay development, validation, and outsourcing. Her industry career started at Merck Research Laboratories at Rahway, New Jersey. Yan actively volunteers for the American Association of Pharmaceutical Scientists (AAPS) and is a founding member on the Leadership teams of the AAPS Biomarkers and Precision Medicine Community and the Gene and Cell Therapeutic Product Communities. She holds several patents and is a co-author of several industry white papers in biomarker assay development and validation.